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A new formulation of metformin: metformin extended-
release (ER) is now available, with different formulations
in each country and it appears relevant to discuss the
management of this drug in clinical practice. Metformin, an
oral biguanide hypoglycemic agent, is an efficacious tool in
the treatment of type 2 diabetes mellitus. Metformin’s
efficacy, security profile, benefic cardiovascular and met-
abolic effects make this drug as the first agent of choice in
the treatment of type 2 diabetes, together with lifestyle
modifications [1]. Type 2 diabetes is characterized by
impaired insulin secretion and insulin resistance. Insulin
resistance in the fasting state induces an increase in hepatic
gluconeogenesis and induces hyperglycemia in the early
morning. Metformin, as its major effect, decreases hepatic
glucose output lowering fasting glycaemia and, secondar-
ily, it increases glucose uptake in peripheral tissues. It is
generally well tolerated, despite the fact that the most
common adverse effects are gastrointestinal ones, which
may be tampered by dose titration. In monotherapy met-
formin decreases HbA1c levels by 0.6–1.0 % and this is
not accompanied by hypoglycemia in the large majority of
patients. Metformin is neutral with respect to weight or,
possibly, induces a modest weight loss. The UKPDS has
demonstrated a beneficial effect of metformin therapy on
CVD outcomes [2]. Severe renal dysfunction is considered
a contraindication to metformin use, because it may
increase the risk of lactic acidosis; therefore, therapy
should be discontinued if the estimated glomerular filtra-
tion rate falls below 30 ml/min. The pharmacokinetic
characteristics of the conventional immediate-release (IR)
formulation of metformin need three times daily dosing.
Metformin is primarily used to treat type 2 diabetes, but it
is also beneficial in the treatment of other metabolic dis-
eases such as the polycystic ovarian syndrome (PCOS) and
the non alcoholic fat liver disease (NAFLD).
Metformin ER was obtained using a Gelshield diffusion
system that gives to metformin a slower absorption than IR
with a maximum plasma concentration of 7 h versus 3.
Metformin ER releases the active drug through hydrated
polymers which expand safe uptake of fluid, prolonging
gastric transit and slowering drug absorption in the upper
gastrointestinal tract [3]. The extent of absorption is
equivalent for both formulations. The maximum plasma
concentrations (Cmax) of metformin ER 2,000 mg once
daily is higher than metformin 1,000 mg twice a day.
Metformin ER is well tolerated at single dose and there is
no accumulation with multiple dose administration [4].
Many studies have demonstrated that once or twice daily
administration of ER metformin is as safe and efficacious
as twice daily IR metformin, overall providing continued
glycemic control for up to 24 weeks of treatment [5]. A
prospective open label study has shown that metformin ER
was efficacious on blood glucose, lipid profile and blood
pressure [6]. While metformin IR maintains efficacious
concentration up to 6 h, the efficacy of metformin ER is
about 12 h. This means that if in the current clinical setting
IR metformin needs three time daily dosing, we should use
twice daily ER metformin dose because in the current
clinical setting, twice daily ER metformin is equivalent to a
three time daily dose of IR metformin and once a day ER
metformin is equivalent to twice daily IR metformin. In
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Table 1 a comparison between the characteristics of met-
formin ER versus those of metformin IR are reported.
Which advantages presents metformin ER with respect
to metformin IR?
First of all, it enables a less number of doses daily and this
improves the patient compliance to therapy. Besides,
metformin ER has a slow absorption without a rapid peak
in blood stream and this produces less side gastrointestinal
effects [7–9]. The last, but not the least, advantage is to
reduce glycemia in the early morning which ameliorates
the glycemic control of patients.
Conclusions
Metformin ER is associated by less gastrointestinal side
effects. Moreover, it needs less frequent daily doses
because of the drug pharmacokinetics, but, despite the
opinion of some authors [4–6] suggesting the use metfor-
min ER once a day, in our opinion it is strongly recom-
mendable to use at least two time daily dose because of all
the reasons described above. These considerations, all
together, contribute to improve the patient compliance to
the therapy. In addition, since there are different formula-
tions of metformin ER in each country, we can suggest to
replace the total daily dose of metformin IR with the same
daily dose of metformin ER divided twice a day. We do not
recommend the use of metformin ER in once daily dosing
because of its pharmacokinetics, in fact, if this drug has a
duration of 12 h, under these condition it is not able to
cover neither the inter prandial phase in a day, nor the
morning hyperglycemia. Moreover in PCOS and NAFLD,
diseases in which it is important to reduce insulin
resistance during a 24 h period, the use of metformin ER
could improve the efficacy of this therapeutical approach.
Metformin ER could have also beneficial effects in predi-
abetes conditions and in obesity [10].
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Duration (hours) 12 6
Daily times dosing 2 3
Maximum plasma concentration (hours) 7 3
GI side effects - ?
HbA1c Reduction (%) 0.6–1 0.6–1
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